322 results found

On April 15, 2024, in response to feedback on last year's ANPRM, Director Vidal issued an invitation to comment on the new NPRM governing PTAB review practices...

On Wednesday, March 11, 2026, United States Patent and Trademark Office (USPTO) Director John Squires issued a memorandum announcing that when making institution decisions in inter partes review (IPR) and post-grant review (PGR) proceedings, he would consider whether accused or licensed products and components were manufactured in the United States, as well as whether the petitioner was a small business that had been sued for infringement.

USPTO Director Vidal continues to take an active role in inter partes reviews, granting Director review of a set of discretionary denials of institution under § 325(d).

A hip-hop artist has blamed his trial loss on AI used in the closing. After asking for a new trial, will there be a claim for malpractice? But will that succeed?

For those who have not had a chance to attend one of our CLE presentations on Litigation Funding Disclosure, this IAM article provides a glimpse of the complex landscape for defendants...

When the Federal Circuit resurrected Amarin's "skinny label" infringement claims against Hikma last month, it offered some important lessons for drug developers.

The FTC and DOJ have continued their efforts to take action against private equity firms for engaging in serial acquisitions (so-called "roll-ups"). The agencies claim that these deals increase...

Below are the top takeaways from the "Has Competition in the US Been Declining?" panel that antitrust lawyers should keep on their radar.

Axinn managing partner Jeny Maier co-hosted ABA's Our Curious Amalgam podcast in an episode entitled, "What's Up With U.S. Merger Remedies?"

FDA announced on October 11, 2023 that it is creating a new Digital Health Advisory Committee to provide guidance to FDA on issues relating to digital health technologies ("DHTs")...

As discussed last month, the FTC sent letters to 10 pharmaceutical companies, asserting that their listing of over 100 patents in FDA's Orange Book for a variety of products was improper.

A trade secret owner must file a civil action under the Defend Trade Secrets Act ("DTSA") within three years of when the alleged trade secret misappropriation...

The 2024 ABA/IBA International Cartel Workshop in Barcelona, Spain just wrapped up after three days full of demonstrations around a cartel hypothetical, substantive panels...

The Spring Meeting is the largest gathering of competition, consumer protection, and data privacy profes­sionals globally, with lawyers, academics, economists, enforcers, journalists, and students from around the world.

At the American Bar Association's annual Spring Meeting on April 2–4, 2025, an economist and a group of antitrust practitioners, including Axinn partner Leslie Overton.

Retail mergers have increasingly captured public and regulatory attention as consumers grow concerned about consolidation and its impact on prices and competition.

The 40th American Bar Association White Collar Crime Conference took place on March 5-7, 2025 in Miami, and was once again loaded with timely discussion on a range of U.S. criminal enforcement topics.

In the continuing debate over the uptake of biosimilars, FDA recently put a stake in the ground by recommending in a new labeling guidance that all biosimilar products contain only a biosimilarity statement...